CellChorus has landed its latest SBIR award. Photo via Getty Images

Houston-based CellChorus and Stanford Medicine were recently awarded a Phase I Small Business Innovation Research grant for the company's AI platform to test how certain cancer patients will respond to therapies.

The funding comes from the National Cancer Institute of the National Institutes of Health. According to a filing, the grant totaled just under $400,000.

CellChorus, which spun out from the University of Houston’s Technology Bridge, has developed TIMING (Time-lapse Imaging Microscopy In Nanowell Grids), which analyzes the behavior of thousands of individual immune cells over time and can identify early indicators of treatment success or failure.

The company will work with Stanford's Dr. David Miklos and Dr. Saurabh Dahiya, who have built the Bone Marrow Transplantation and Cell Therapy Biobank. The biobank manages and stores biological samples from patients treated at their clinic and in clinical trials.

"Predicting which patients will achieve durable responses after CAR-T therapy remains one of the most important challenges in the field,” Miklos said in a news release. “We aim to uncover functional cellular signatures that can guide treatment decisions and improve patient outcomes.”

The project will specifically profile cells from patients with relapsed/refractory large B-cell lymphoma (r/rLBCL). According to CellChorus, only about half of r/rLBCL patients who receive CAR-T therapy "achieve a durable, long-term remission." Others do not respond to therapy or experience relapse.

“The sooner we know whether a cancer therapy is working, the better. To maximize patient benefit, we need technology that can provide a robust and early prediction of response to therapy. The technology needs to be scalable, cost-efficient, and capable of rapid turnaround times,” Rebecca Berdeaux, chief scientific officer of CellChorus, added in the release. “We are excited to work with Drs. David Miklos and Saurabh Dahiya and their colleagues on this very important project.”

CellChorus has previously received SBIR grants from federal agencies, including a $2.5 million award in 2024 from its National Center for Advancing Translational Sciences (NCATS) and a $2.3 million SBIR Fast-Track award from the National Institute of General Medical Sciences in 2023.

CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding. Photo via Getty Images

University of Houston-founded company secures $2.5M in NIH grant funding

all in the timing

You could say that the booming success of Houston biotech company CellChorus owes very much to auspicious TIMING. Those six letters stand for Time-lapse Imaging Microscopy In Nanowell Grids, a platform for dynamic single-cell analysis.

This week, CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding from the National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health. A $350,000 Phase I grant is already underway. Once predetermined milestones are achieved, this will lead to a two-year $2.1 million Phase II grant.

The TIMING platform was created by UH Single Cell Lab researchers Navin Varadarajan and Badri Roysam. TIMING generates high-throughput in-vitro assays that quantitatively profile interactions between cells on a large scale, particularly what happens when immune cells confront target cells. This has been especially useful in the realm of immuno-oncology, where it has demonstrated its power in designing novel therapies, selecting lead candidates for clinical trials and evaluating the potency of manufactured cells.

“By combining AI, microscale manufacturing and advanced microscopy, the TIMING platform yields deep insight into cellular behaviors that directly impact human disease and new classes of therapeutics,” says Rebecca Berdeaux, chief scientific officer at CellChorus. “The generous support of NCATS enables our development of computational tools that will ultimately integrate single-cell dynamic functional analysis of cell behavior with intracellular signaling events.”

Houston’s CellChorus Innovation Lab supports both the further development of TIMING and projects for early-access customers. Those customers include top-25 biopharmaceutical companies, venture-backed biotechnology companies, a leading comprehensive cancer center and a top pediatric hospital, says CEO Daniel Meyer.

CellChorus’s publications include papers written in collaboration with researchers from the Baylor College of Medicine, Houston Methodist, MD Anderson, Texas Children’s Hospital, the University of Texas and UTHealth in journals including Nature Cancer, Journal of Clinical Investigation and The Journal for ImmunoTherapy of Cancer.

The new Small Business Technology Transfer (STTR) award will specifically support the development of a scalable integrated software system conceived with the goal of analyzing cells that are not fluorescently labeled. This label-free analysis will be based on new AI and machine learning (ML) models trained on tens of millions of images of cells.

“This is an opportunity to leverage artificial intelligence methods for advancing the life sciences,” says Roysam. “We are especially excited about its applications to advancing cell-based immunotherapy to treat cancer and other diseases.”

The Houston-born-and-bred company couldn’t have a more appropriate home, says Meyer.

“Houston is a premier location for clinical care and the development of biotechnology and life sciences technologies. In particular, Houston has established itself as a leader in the development and delivery of immune cell-based therapies,” the CEO explains. “As a spin-out from the Single Cell Lab at the University of Houston, we benefit from working with world-class experts at local institutions.”

In May, the company received a similar $2.5 million SBIR grant from NCATS at the NIH. Also this summer, CellChorus's technology was featured in Nature Cancer.

This uniquely Houston technology is an AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement. Photo via Getty Images

University of Houston lab reports breakthrough in cancer-detecting technology

making moves

T-cell immunotherapy is all the rage in the world of fighting cancer. A Houston company’s researchers have discovered a new subset of T cells that could be a game changer for patients.

CellChorus is a spinoff of Navin Varadarajan’s Single Cell Lab, part of the University of Houston’s Technology Bridge. The lab is the creator of TIMING, or Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visual AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement.

Last month, Nature Cancer published a paper co-authored by Varadarajan entitled, “Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling.”

“Our results showed that a subset of T cells, labeled as CD8-fit T cells, are capable of high motility and serial killing, found uniquely in patients with clinical response,” says first author and recent UH graduate Ali Rezvan in Nature Cancer.

Besides him and Varadarajan, contributors hail from Baylor College of Medicine/Texas Children’s Hospital, MD Anderson Cancer Center, Kite Pharma, and CellChorus itself.

The team identified the CD80-fit T cells using TIMING to examine interactions between T cells and tumor cells across thousands of individual cells. They were able to integrate the results using single-cell RNA sequencing data.

T-cell therapy activates a patient’s own immune system to fight cancer cells, but not every patient responds favorably to it. Identifying CD8-fit cells could be the key to manufacturing clinical response even in those for whom immunotherapy hasn’t been effective.

“This work illustrates the excellence of graduate students Ali Rezvan and Melisa Montalvo; and post-doctoral researchers Melisa Martinez-Paniagua and Irfan Bandey among others,” says Varadarajan in a statement.

Earlier last month, CellChorus recently received a $2.5 million SBIR grant. The money allows the company to share TIMING more widely, facilitating even more landmark discoveries like CD8-fit cells.

CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

Houston health tech startup scores $2.5M SBIR grant to advance unique cell therapy AI technology

fresh funding

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

The 2023 Houston Innovation Awards celebrated Houston's tech and entrepreneurship community. Photo by Emily Jaschke/InnovationMap

Photos: Houston innovation ecosystem celebrates wins at annual event

Houston Innovation Awards

That's a wrap on the 2023 Houston Innovation Awards — and boy did the event deliver on networking, award wins, and plenty of celebrating Houston's tech and entrepreneurship community.

With a crowd of around 600 attendees, the Houston Innovation Awards, which took place on November 8 at Silver Street Studios in partnership with Houston Exponential, celebrated over 50 finalists and a dozen winners across categories. Click here to see who won an award.

Learn more about this year's honorees in InnovationMap's the editorial series:

See below for photos from the event.

The 2023 Houston Innovation Awards took place on Nov. 8.

Photo by Emily Jaschke/InnovationMap

The 2023 Houston Innovation Awards revealed its big winners across 13 categories. Photos courtesy

Houston Innovation Awards winners revealed at 2023 event

drum roll, please...

Who are the top innovators and startups in Houston? We just found out for you.

The Houston Innovation Awards honored over 50 finalists categories, naming the 12 winners at the event. The 2023 Trailblazer Award recipient, Brad Burke, managing director of the Rice Alliance for Technology and Entrepreneurship, was also honored at the event by inaugural winner, Barbara Burger.

The 2023 judges — who represent various industries and verticals in Houston — scored over 200 submissions. The event, hosted November 8 in partnership with Houston Exponential and emceed by Scott Gale, executive director of Halliburton Labs, revealed the winners.

The event's sponsors included Halliburton Labs, Microsoft, The Ion, Houston Community College, Houston Energy Transition Initiative, NOV, Tito's Handmade Vodka, Uncle Nearest Premium Whisky, 8th Wonder Brewery, and 8th Wonder Cannabis.

Without further adieu, here the winners from the 2023 Houston Innovation Awards.

BIPOC-Owned Business: Milkify

The winner of the BIPOC-Owned Business category, honoring an innovative company founded or co-founded by BIPOC representation, is Milkify, a service that turns breast milk into a shelf-stable powder.

Female-Owned Business: The Postage

The winner of the Female-Owned Business category, honoring an innovative company founded or co-founded by a woman, is The Postage, a comprehensive life planning and succession software platform for families and small businesses.

Hardtech Business: Syzygy Plasmonics

The winner of the Hardtech Business category, honoring an innovative company developing and commercializing a physical technology, is Syzygy Plasmonics, a deep decarbonization company that builds chemical reactors designed to use light instead of combustion to produce valuable chemicals like hydrogen and sustainable fuels.

Digital Solutions Business: RepeatMD

The winner of the Digital Solutions Business category, honoring an innovative company developing and programming a digital solution to a problem in an industry, is RepeatMD, software platform for customer loyalty, eCommerce, and fintech solutions to enhance the patient experience and provide a new source of revenue for the aesthetics and wellness space.

Social Impact Business: ALLY Energy

The winner of the Social Impact Business category, honoring an innovative company providing a solution that would enhance humanity or society in a significant way, is ALLY Energy, helping energy companies and climate startups find, develop, and retain great talent.

Sustainability Business: Fervo Energy

The winner of the Sustainability Business category, honoring an innovative company providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond, is Fervo Energy, leveraging proven oil and gas drilling technology to deliver 24/7 carbon-free geothermal energy.

Life Science Business: CellChorus

The winner of the Life Science Business category, honoring an innovative company within the health and medical industries designing a treatment or technology, is CellChorus, using AI to evaluate immune cell function and performance to improve the development and delivery of therapeutics.

Corporate of the Year: Houston Methodist

The winner of the Corporate of the Year category, honoring a corporation that supports startups and/or the Houston innovation community, Houston Methodist, a hospital system and health care innovation leader.

DEI Champion: Calicia Johnson

The winner of the DEI Champion, honoring an individual who is leading impactful diversity, equity, and inclusion initiatives and progress within Houston and their organization, is Calicia Johnson, chair of Blacks at Microsoft Houston.

Ecosystem Builder: Joey Sanchez

The winner of the Ecosystem Builder category, honoring an individual who has acted as a leader in developing Houston’s startup ecosystem, is Joey Sanchez, founder of Cup of Joey and senior director of ecosystems at the Ion.

Mentor of the Year: Wade Pinder

The winner of the Mentor of the Year category, honoring an individual who dedicates their time and expertise to guide and support to budding entrepreneurs, is Wade Pinder, founder of Product Houston.

People's Choice: 

The winner of the People's Choice: Startup of the Year category, selected via an interactive voting portal during the event, is Blue People, helping bring ideas to life through software development expertise.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston e-commerce giant Cart.com launches government-focused subsidiary

government branch

Houston e-commerce and logistics unicorn Cart.com has launched a new subsidiary.

Cart Government Solutions (CGS), which was announced earlier this week, will provide supply chain and logistics services and software for the federal and state government sectors. The new subsidiary will be headquartered in Washington, D.C., and operate out of about 6 million square feet of secure warehouse space across 14 U.S. facilities, according to a news release from Cart.com. It will support both domestic and overseas logistics.

Industry veteran Gregg Zegras will lead the new entity as president. Zegras previously served as Cart.com's chief revenue officer, according to LinkedIn. Before that, he served as president of Connecticut-based Pitney Bowes Global eCommerce, a digital shipping solutions company.

Remington Tonar, Cart.com's co-founder, will serve as CGS's chief innovation officer.

“Government agencies face procurement and logistics challenges that many commercial platforms simply weren’t built to solve,” Zegras said in the news release. “Cart Government Solutions exists to change that. We’re combining the speed and innovation of a technology company with the compliance rigor, security, and operational depth that federal and state customers require, and we’re doing it with a team that has spent careers working alongside and inside these agencies.”

According to the company, CGS will focus on meeting compliance and security requirements in the public sector. Some of the services the new entity will offer include:

  • Inventory management
  • Cold-chain and specialty storage for pharmaceuticals, medical devices and regulated goods
  • Enterprise-grade supply chain software
  • Government-compliant webstores and online ordering portals
  • Cybersecurity operations

Cart.com has been serving the public sector since 2022, when the company began distributing COVID-19 health supplies nationwide, according to the news release. Through that pandemic-era contract, the company reports it moved more than 725 million units, with an average of under two days per shipment.

Cart.com was founded in Houston in 2020, though it briefly moved its headquarters to Austin. The company reached unicorn status with its $60 million Series C raise in 2023. It most recently raised $180 million in growth capital from private equity firm Springcoast Partners in March, which put the startup over the $1 billion in fundraising mark in just six years.

At the time, Cart.com said it planned to scale its logistics network, expand AI capabilities and develop workflow automation tools.

Houston-based KBR Inc. also recently launched a government services spinoff. Read more here.

2 Houston universities named best colleges of 2027 by Princeton Review

A-Plus Ratings

Back-to-school season is has returned in full force, and that means it's time for college rankings. Two Houston universities in particular are being hailed as the top of the class for 2027.

The high caliber schools — Rice University and University of Houston — earned new acclaim in The Princeton Review's ranking of the "Best 392 Colleges" for 2027.

The Princeton Review's 35th annual "Best Colleges" rankings are determined by a survey of 172,000 current college students that gave "candid feedback" about their schools and their experiences. The flagship guide does not rank the schools overall, but it does rank them across 50 different categories, including best-run colleges, best quality of life, happiest students, best athletic facilities, among others.

In all, 14 Texas institutions were highlighted in the overall list of the 392 best colleges.

Schools don't pay to be included in the guide, but The Princeton Review clarified that schools could pay for a "featured" designation. No Houston university paid to be featured in this year's guide. Trinity University in San Antonio and Southwestern University, a private school in the Austin suburb Georgetown, were the only two Texas schools that paid to be "featured."

Rice and UH have been on a winning streak in separate reports of the best universities worldwide, best graduate schools, and best online degree programs.

In addition to being included in the overall list, Rice was highlighted as one of the Best Value Colleges, Colleges That Create Futures, and it earned high marks in Princeton Review's Mental Health Honor Roll 2026. The home of the Rice Owls also starred in the regional Best Southwest list that contained 41 universities across Arizona, Colorado, New Mexico, Oklahoma, and Texas.

"Rice University stands out as a leading research university where academic diversity and a wide array of interdisciplinary institutes and centers make it easy for students to explore multiple areas of interest," the school's profile says. "At Rice, 'knowledge isn’t siloed — students are constantly crossing disciplines and interests in ways that feel natural rather than exceptional.'"

Rice earned the following rankings on 14 other lists:

  • No. 1 – Lots of Race/Class Interaction
  • No. 3 – Best College Newspaper
  • No. 9 – Friendliest Students
  • No. 11 – Best Quality of Life
  • No. 13 – Great Financial Aid
  • No. 14 – Top 50 Best Value Private Colleges
  • No. 17 – Their Students Love These Colleges
  • No. 18 – Top 20 Best Value Private Colleges Without Aid
  • No. 18 – Best Student Support and Counseling Services
  • No. 19 – Best College Dorms
  • No. 21 – Students Study the Most
  • No. 24 – Best Campus Food
  • No. 24 – Best College Radio Station
  • No. 24 – Best-Run colleges
The University of Houston also appeared in the Best Southwest, Best Value Colleges, and Colleges That Create Futures lists, and it was named a top Green College, which examined schools that "share superb sustainability practices, a strong foundation in sustainability education, and a healthy quality of life for students on campus

UH earned five more accolades:

  • No. 1 – Top 50 Undergraduate Schools for Entrepreneurship Studies
  • No. 1 – Top Undergraduate Schools for Entrepreneurship Studies in the Southwest
  • No. 8 – Most Politically Moderate Students
  • No. 15 – Financial Aid Not So Great
  • No. 42 – Top 50 Best Value Public Colleges
In the school's profile, students say they had an overall positive experience thanks to UH's excellent academic offerings and dedicated faculty members.

"Students confirm that 'the research and other academic opportunities... are very accessible to students who seek it out,'" the profile says. "This includes taking advantage of UH’s vast alumni network (more than 325,000 and counting), not to mention its location in the corporate center of Houston, where 'the opportunities that are provided are immense.'"

The 12 other public and private universities in Texas included in The Princeton Review's 2027 guide are:

  • The University of Texas at Austin
  • Southwestern University, Georgetown
  • Baylor University, Waco
  • Texas A&M University - College Station
  • Trinity University, San Antonio
  • Texas State University, San Marcos
  • Angelo State University, San Angelo
  • Texas Christian University, Fort Worth
  • University of Dallas, Irving
  • Southern Methodist University, Dallas
  • The University of Texas at Dallas, Richardson
  • Austin College, Sherman
---

A version of this story originally appeared on CultureMap.com.

Houston named the No.1 emerging city for biopharma in inaugural report

Biopharma Leader

Houston is ranked No.1 on the first-ever Next 10 U.S. Biopharma Clusters report published by Genetic Engineering & Biotechnology News (GEN).

The report, which ranks the best emerging hubs for life science activities, considered patents, NIH funding, lab space, venture capital investments, and the number of jobs in regions in cities, states and “clusters” across the U.S. GEN touts Houston as the top city for the biopharma industry due to a surge in funding, job creation, medical innovations and startup success.

Here’s how Houston ranked in the report’s different categories;

  • No. 1 for NIH funding with 2,262 awards totaling more than $1.25 billion
  • No. 2 for emerging regions for jobs, with 28,000 jobs
  • No. 2 for lab space, with roughly 8 million square feet in the market
  • No. 6 for patents, with 2,760 patent families

According to BioHouston chairman Jeff Wade, Houston secured half a billion dollars in venture capital funding in 2025 and 2026 to date.

The report called out major biopharm news out of Houston in the last few months, including Bristol Myers Squibb selecting Houston for its $1 billion, 600,000-square-foot manufacturing site and Eli Lily selecting Houston for its $6.5 billion, 236-acre manufacturing site. Both facilities will be located within Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston.

Houston startups like CrossBridge Bio and Duracyte were also mentioned in the report. CrossBridge, which develops antibody-drug conjugates for cancer, was acquired by Eli Lily in April for $300 million. Duracyte, a “living pharmacy” company, was launched out of Rice University’s biotech venture studio RBL LLC this spring and is backed by up to a $45 million Advanced Research Projects Agency for Health (ARPA-H) award.

The startup is working to commercialize its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR) technology, a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time.

“There’s a lot of great talent, but the unique advantage that we have is we are able to benefit from a lot of unique clinical infrastructure and clinician insights,” Omid Veiseh, Duracyte co-founder and managing partner of RBL LLC, told GEN. “There are a lot of clinicians here who are eager to partner on investigator-initiated trials.”

The report also touted Houston’s Texas Medical Center, home to the University of Texas MD Anderson Cancer Center and Baylor College of Medicine, and international partnerships like the recently expanded TMC Korea BioBridge.

Other cities to make the list include:

  • No. 2 Minneapolis-St. Paul
  • No. 3 Denver-Boulder
  • No. 4 St. Louis
  • No. 5 Dallas-Fort Worth

States to make the list include:

  • No. 1 Ohio (including Cincinnati, Cleveland, and Columbus)
  • No. 2 Indiana (including Indianapolis)
  • No. 3 Florida (including Jacksonville and Miami-Fort Lauderdale)
  • No. 4 Georgia (including Atlanta and Augusta)
  • No. 5 Wisconsin (including Madison and Kenosha)

Regional state clusters to watch include:

  • Phoenix
  • Pittsburgh
  • Greater Richmond, Virginia
  • South Carolina
  • Utah

See the full report here.